熱門資訊> 正文

Biogen Leqembi治疗阿尔茨海默氏症的家庭维持剂量可用

2025-10-07 05:11

Eisai (OTCPK:ESALF) and Biogen (NASDAQ:BIIB) have launched Leqembi IQLIK, a subcutaneous version of their Alzheimer's medication Leqembi (lecanemab) to be given as maintenance doses.
Patients on the treatment must first receive Leqembi as an infusion given every four weeks for 18 months before they can start using the IQLIK autoinjector version, which is taken weekly.
The two companies also unveiled the Leqembi Companion program, which includes access to nurse educators for instructions on how to administer the injections and patient support.
The US FDA approved Leqembi IQLIK in late August.

More on Biogen, Eisai

Biogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript
Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Biogen gets complete response letter from FDA for higher dose Spinraza
Biogen to buy Massachusetts-based Alcyone Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。